Please note this appraisal has now been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | STA Standard |
| ID number | 1529 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 January 2024 | Discontinued. Please note this appraisal has now been discontinued. |
| 03 April 2020 | In progress. Topic is in progress |
| 03 April 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Inebilizumab within its marketing authorisation for reducing the risk of attacks and worsening of disability in patients with neuromyelitis optica spectrum disorders. Please note that following advice received from the company, further information regarding the timelines for this appraisal will be available in due course. |
| 02 September 2019 (14:00) | Scoping workshop (Manchester) |
| 18 July 2019 - 15 August 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual